AstraZeneca and Daiichi Sankyo to jointly develop another new cancer treatment
30-07-2020
AstraZeneca partners on AI drug discovery collaboration
02-05-2019
Roland Magnusson / Shutterstock.com
AstraZeneca is planning to build a new global research and development centre in China.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
AstraZeneca, China, research and development, medicine, artificial intelligence, China International Capital Corporation, big pharma
